Cargando…
Temozolomide Therapy for Aggressive Pituitary Tumors: Results in a Small Series of Patients from Argentina
We evaluated results of temozolomide (TMZ) therapy in six patients, aged 34–78 years, presenting aggressive pituitary tumors. In all the patients tested O(6)-methylguanine-DNA methyltransferase (MGMT) immunoexpression in surgical specimens was absent. Patients received temozolomide 140–320 mg/day fo...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Hindawi Publishing Corporation
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4461777/ https://www.ncbi.nlm.nih.gov/pubmed/26106414 http://dx.doi.org/10.1155/2015/587893 |
_version_ | 1782375552911409152 |
---|---|
author | Bruno, Oscar D. Juárez-Allen, Lea Christiansen, Silvia B. Manavela, Marcos Danilowicz, Karina Vigovich, Carlos Gómez, Reynaldo M. |
author_facet | Bruno, Oscar D. Juárez-Allen, Lea Christiansen, Silvia B. Manavela, Marcos Danilowicz, Karina Vigovich, Carlos Gómez, Reynaldo M. |
author_sort | Bruno, Oscar D. |
collection | PubMed |
description | We evaluated results of temozolomide (TMZ) therapy in six patients, aged 34–78 years, presenting aggressive pituitary tumors. In all the patients tested O(6)-methylguanine-DNA methyltransferase (MGMT) immunoexpression in surgical specimens was absent. Patients received temozolomide 140–320 mg/day for 5 days monthly for at least 3 months. In two patients minimum time for evaluation could not be reached because of death in a 76-year-old man with a malignant prolactinoma and of severe neutro-thrombopenia in a 47-year-old woman with nonfunctioning pituitary adenoma. In two patients (a 34-year-old acromegalic woman and a 39-year-old woman with Nelson's syndrome) no response was observed after 4 and 6 months, respectively, and the treatment was stopped. Conversely, two 52- and 42-year-old women with Cushing's disease had long-term total clinical and radiological remissions which persisted after stopping temozolomide. We conclude that TMZ therapy may be of variable efficacy depending on—until now—incompletely understood factors. Cooperative work on a greater number of cases of aggressive pituitary tumors should be crucial to establish the indications, doses, and duration of temozolomide administration. |
format | Online Article Text |
id | pubmed-4461777 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2015 |
publisher | Hindawi Publishing Corporation |
record_format | MEDLINE/PubMed |
spelling | pubmed-44617772015-06-23 Temozolomide Therapy for Aggressive Pituitary Tumors: Results in a Small Series of Patients from Argentina Bruno, Oscar D. Juárez-Allen, Lea Christiansen, Silvia B. Manavela, Marcos Danilowicz, Karina Vigovich, Carlos Gómez, Reynaldo M. Int J Endocrinol Clinical Study We evaluated results of temozolomide (TMZ) therapy in six patients, aged 34–78 years, presenting aggressive pituitary tumors. In all the patients tested O(6)-methylguanine-DNA methyltransferase (MGMT) immunoexpression in surgical specimens was absent. Patients received temozolomide 140–320 mg/day for 5 days monthly for at least 3 months. In two patients minimum time for evaluation could not be reached because of death in a 76-year-old man with a malignant prolactinoma and of severe neutro-thrombopenia in a 47-year-old woman with nonfunctioning pituitary adenoma. In two patients (a 34-year-old acromegalic woman and a 39-year-old woman with Nelson's syndrome) no response was observed after 4 and 6 months, respectively, and the treatment was stopped. Conversely, two 52- and 42-year-old women with Cushing's disease had long-term total clinical and radiological remissions which persisted after stopping temozolomide. We conclude that TMZ therapy may be of variable efficacy depending on—until now—incompletely understood factors. Cooperative work on a greater number of cases of aggressive pituitary tumors should be crucial to establish the indications, doses, and duration of temozolomide administration. Hindawi Publishing Corporation 2015 2015-05-27 /pmc/articles/PMC4461777/ /pubmed/26106414 http://dx.doi.org/10.1155/2015/587893 Text en Copyright © 2015 Oscar D. Bruno et al. https://creativecommons.org/licenses/by/3.0/ This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Clinical Study Bruno, Oscar D. Juárez-Allen, Lea Christiansen, Silvia B. Manavela, Marcos Danilowicz, Karina Vigovich, Carlos Gómez, Reynaldo M. Temozolomide Therapy for Aggressive Pituitary Tumors: Results in a Small Series of Patients from Argentina |
title | Temozolomide Therapy for Aggressive Pituitary Tumors: Results in a Small Series of Patients from Argentina |
title_full | Temozolomide Therapy for Aggressive Pituitary Tumors: Results in a Small Series of Patients from Argentina |
title_fullStr | Temozolomide Therapy for Aggressive Pituitary Tumors: Results in a Small Series of Patients from Argentina |
title_full_unstemmed | Temozolomide Therapy for Aggressive Pituitary Tumors: Results in a Small Series of Patients from Argentina |
title_short | Temozolomide Therapy for Aggressive Pituitary Tumors: Results in a Small Series of Patients from Argentina |
title_sort | temozolomide therapy for aggressive pituitary tumors: results in a small series of patients from argentina |
topic | Clinical Study |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4461777/ https://www.ncbi.nlm.nih.gov/pubmed/26106414 http://dx.doi.org/10.1155/2015/587893 |
work_keys_str_mv | AT brunooscard temozolomidetherapyforaggressivepituitarytumorsresultsinasmallseriesofpatientsfromargentina AT juarezallenlea temozolomidetherapyforaggressivepituitarytumorsresultsinasmallseriesofpatientsfromargentina AT christiansensilviab temozolomidetherapyforaggressivepituitarytumorsresultsinasmallseriesofpatientsfromargentina AT manavelamarcos temozolomidetherapyforaggressivepituitarytumorsresultsinasmallseriesofpatientsfromargentina AT danilowiczkarina temozolomidetherapyforaggressivepituitarytumorsresultsinasmallseriesofpatientsfromargentina AT vigovichcarlos temozolomidetherapyforaggressivepituitarytumorsresultsinasmallseriesofpatientsfromargentina AT gomezreynaldom temozolomidetherapyforaggressivepituitarytumorsresultsinasmallseriesofpatientsfromargentina |